GlassScriptPhysician profile
Dana C Barnes
NPI 1013178581
$12,491.78
in general payments reported to CMS, 2019-2025
28 companies · $2,247 in 2025
The $2,247 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,009 · 2020: $995 · 2021: $1,597 · 2022: $1,513 · 2023: $1,721 · 2024: $2,409 · 2025: $2,247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,136 · Travel and Lodging: $242.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,135.66 |
| Travel and Lodging | $241.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $3,943.53 | 2019-2025 | Dovato, Cabenuva, Rukobia |
| Gilead Sciences, INC. | $2,920.23 | 2019-2025 | |
| Theratechnologies INC. | $1,452.74 | 2019-2025 | Egrifta, Trogarzo |
| Merck Sharp & Dohme LLC | $1,376.06 | 2019-2025 | Pifeltro, Delstrigo, Capvaxive |
| Abbvie INC. | $926.97 | 2019-2025 | Mavyret |
| Janssen Biotech, INC. | $737.09 | 2019-2023 | Symtuza |
| Napo Pharmaceuticals INC | $236.02 | 2019-2025 | Mytesi |
| Emd Serono, INC. | $141.76 | 2019-2025 | Serostim |
| Janssen Products, LP | $99.95 | 2019 | |
| Pfizer INC. | $66.57 | 2021-2025 | |
| Glaxosmithkline, LLC. | $64.55 | 2019-2021 | |
| Exact Sciences Corporation | $63.71 | 2024-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.80 | 2020-2022 | |
| Hologic Sales and Service, LLC | $60.79 | 2023-2025 | Aptima |
| Lilly USA, LLC | $58.08 | 2019-2025 | Mounjaro |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $43.23 | 2020-2021 | |
| Esperion Therapeutics, INC. | $34.43 | 2021 | |
| Janssen Scientific Affairs, LLC | $25.04 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $24.00 | 2019 | |
| Astellas Pharma US INC | $23.07 | 2025 | Veozah |
| Csl Behring | $21.77 | 2024 | Hizentra |
| Novo Nordisk INC | $19.93 | 2024 | |
| Novartis Pharmaceuticals Corporation | $19.16 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.15 | 2025 | |
| Paragon 28, INC. | $15.84 | 2023 | Activcore Nail |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.34 | 2019 | |
| Amgen INC. | $12.90 | 2021 | |
| Antares Pharma, INC. | $12.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Barnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.